2022 Announcements

CLINUVEL
Posted by CLINUVEL
April 29, 2022

CEO letter

For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...

Read More
CLINUVEL
Posted by CLINUVEL
April 28, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
April 27, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 8, 2022

CLINUVEL Kommuniqué II

At CLINUVEL our path has been set and we continue to grow...

Read More
CLINUVEL
Posted by CLINUVEL
April 7, 2022

Initial Director’s Interest Notice

Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 6, 2022

Chair's Letter

In my first letter to you for 2022 I provide updates on...

Read More
CLINUVEL
Posted by CLINUVEL
April 4, 2022

CLINUVEL appoints new Non-Executive Director

Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
Lachlan Hay
Posted by Lachlan Hay
April 1, 2022

CLINUVEL Extends Employment Agreement With CEO

CLINUVEL today announced that it has extended the Employment Agreement with the...

Read More
CLINUVEL
Posted by CLINUVEL
April 1, 2022

DNA Repair Communiqué II

In this DNA Repair Communiqué II we delve deeper into the topic...

Read More
CLINUVEL
Posted by CLINUVEL
March 31, 2022

CLINUVEL Communiqué II

At CLINUVEL our path has been set and we continue to grow...

Read More
CLINUVEL
Posted by CLINUVEL
March 30, 2022

First XP-V Patient Treated in CLINUVEL DNA Repair Study

CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...

Read More
CLINUVEL
Posted by CLINUVEL
March 23, 2022

Change of Director's Interest Notice

Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 17, 2022

ACTH Manufacturing Update

CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...

Read More
CLINUVEL
Posted by CLINUVEL
March 15, 2022

Afamelanotide in stroke (AIS) – positive preliminary results

CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2022

Change of Director's Interest Notice

Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More